Alliance Pharma plc (LSE:APH) — Market Cap & Net Worth
Market Cap & Net Worth: Alliance Pharma plc (APH)
Alliance Pharma plc (LSE:APH) has a market capitalization of $4.26 Million (GBX34.97 Billion) as of May 4, 2026. Listed on the LSE stock exchange, this UK-based company holds position #28657 globally and #505 in its home market, demonstrating a 0.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alliance Pharma plc's stock price GBX64.70 by its total outstanding shares 540566016 (540.57 Million). Analyse Alliance Pharma plc cash flow conversion to see how efficiently the company converts income to cash.
Alliance Pharma plc Market Cap History: 2015 to 2025
Alliance Pharma plc's market capitalization history from 2015 to 2025. Data shows growth from $2.54 Million to $4.26 Million (2.77% CAGR).
Index Memberships
Alliance Pharma plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$928.14 Million | 0.46% | #43 of 722 |
Weight: Alliance Pharma plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alliance Pharma plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alliance Pharma plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Alliance Pharma plc's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.54 Million | $48.34 Million | $12.69 Million | 0.05x | 0.20x |
| 2016 | $2.79 Million | $97.49 Million | $18.09 Million | 0.03x | 0.15x |
| 2017 | $3.99 Million | $103.31 Million | $28.91 Million | 0.04x | 0.14x |
| 2018 | $4.04 Million | $118.21 Million | $18.36 Million | 0.03x | 0.22x |
| 2019 | $5.18 Million | $135.64 Million | $25.01 Million | 0.04x | 0.21x |
| 2020 | $5.43 Million | $129.80 Million | $8.03 Million | 0.04x | 0.68x |
| 2021 | $6.85 Million | $163.21 Million | $7.32 Million | 0.04x | 0.94x |
| 2022 | $3.41 Million | $167.42 Million | -$21.21 Million | 0.02x | N/A |
| 2023 | $2.66 Million | $180.68 Million | -$33.14 Million | 0.01x | N/A |
| 2024 | $3.01 Million | $178.84 Million | -$10.73 Million | 0.02x | N/A |
Competitor Companies of APH by Market Capitalization
Companies near Alliance Pharma plc in the global market cap rankings as of May 4, 2026.
Key companies related to Alliance Pharma plc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Alliance Pharma plc Historical Marketcap From 2015 to 2025
Between 2015 and today, Alliance Pharma plc's market cap moved from $2.54 Million to $ 4.26 Million, with a yearly change of 2.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | GBX4.26 Million | +41.42% |
| 2024 | GBX3.01 Million | +12.96% |
| 2023 | GBX2.66 Million | -21.88% |
| 2022 | GBX3.41 Million | -50.25% |
| 2021 | GBX6.85 Million | +26.23% |
| 2020 | GBX5.43 Million | +4.89% |
| 2019 | GBX5.18 Million | +28.03% |
| 2018 | GBX4.04 Million | +1.43% |
| 2017 | GBX3.99 Million | +42.70% |
| 2016 | GBX2.79 Million | +10.17% |
| 2015 | GBX2.54 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Alliance Pharma plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.26 Million USD |
| MoneyControl | $4.26 Million USD |
| MarketWatch | $4.26 Million USD |
| marketcap.company | $4.26 Million USD |
| Reuters | $4.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alliance Pharma plc
Alliance Pharma plc, a holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated i… Read more